PACE Antibacterial Therapeutics Funding Call
Up to 2 years
Up to £1m
PACE (Pathways to Antimicrobial Clinical Efficacy) aims to provide funding and support for high-value, high-risk, early-phase drug discovery and diagnostic projects.
PACE is looking to help create and advance an exciting and diverse pipeline of preclinical phase projects aimed at treating bacterial infections with high unmet need.
Expressions of interest are invited by 24 November, and an informational webinar will be held on 31 October for interested parties.
Pace’s first funding call will focus solely on early-stage, novel, antibacterial therapeutics.
In-scope indications are:
Projects should be directed at one or more of the following drug-resistant bacteria. They are as follows:
Projects should be transformational, to fill a gap for innovative & differentiated antimicrobials in the clinical pipeline. PACE encourages projects that are based on the concept of precision medicine where consideration is given to potential patient stratification and diagnostics requirements.
PACE intends to fund projects looking at:
Up to 12 applicants will be awarded a maximum of £1 million in grant funding, with projects expected to last up to two years. AMR innovators worldwide are eligible to apply.Contact us